Filing Details
- Accession Number:
- 0001179110-14-002613
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-02-12 17:27:00
- Reporting Period:
- 2014-02-11
- Filing Date:
- 2014-02-12
- Accepted Time:
- 2014-02-12 17:27:00
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1586105 | Egalet Corp | EGLT | Pharmaceutical Preparations (2834) | 463575334 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1591179 | K/S Ii Fund Ventures Science Life Sunstone | Lautrupsgade 7 5Th Floor Copenhagen O G7 DK-2100 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2014-02-11 | 416,812 | $0.00 | 416,812 | No | 4 | C | Direct | |
Common Stock | Acquisiton | 2014-02-11 | 736,826 | $0.00 | 1,153,638 | No | 4 | C | Direct | |
Common Stock | Acquisiton | 2014-02-11 | 96,000 | $0.00 | 1,249,638 | No | 4 | X | Direct | |
Common Stock | Acquisiton | 2014-02-11 | 202,658 | $6.00 | 1,452,296 | No | 4 | C | Direct | |
Common Stock | Acquisiton | 2014-02-11 | 273,986 | $6.00 | 1,726,282 | No | 4 | C | Direct | |
Common Stock | Acquisiton | 2014-02-11 | 133,333 | $12.00 | 1,859,615 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Direct | |
No | 4 | C | Direct | |
No | 4 | X | Direct | |
No | 4 | C | Direct | |
No | 4 | C | Direct | |
No | 4 | P | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series A-1 Preferred Stock | Disposition | 2014-02-11 | 416,812 | $0.00 | 416,812 | $0.00 |
Common Stock | Series B Preferred Stock | Disposition | 2014-02-11 | 736,826 | $0.00 | 736,826 | $0.00 |
Common Stock | Warrants | Disposition | 2014-02-11 | 96,000 | $0.00 | 96,000 | $0.00 |
Common Stock | Subordinated Convertible Debt | Disposition | 2014-02-11 | 0 | $0.00 | 202,658 | $6.00 |
Common Stock | Senior Convertible Debt | Disposition | 2014-02-11 | 0 | $0.00 | 273,986 | $6.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Direct | ||
0 | No | 4 | C | Direct | ||
0 | No | 4 | X | Direct | ||
0 | No | 4 | C | Direct | ||
0 | No | 4 | C | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 154,938 | Indirect | By Egalet A/S |
Footnotes
- The reporting person is Egalet A/S, a corporation. Sunstone Life Science Ventures Fund II K/S ("Sunstone") is a 12.0% equityholder of Egalet A/S.
- The Series A-1 Preferred Stock automatically converted into Egalet Corporation common stock on a 1-for-1 basis immediately prior to the consummation of Egalet Corporation's initial public offering.
- The Series B Preferred Stock automatically converted into Egalet Corporation common stock on a 1-for-1 basis immediately prior to the consummation of Egalet Corporation's initial public offering.
- The warrants were automatically exercised into Egalet Corporation common stock immediately prior to the consummation of the Egalet Corporation's initial public offering on a 1-for-1 basis, pursuant to Sunstone's purchase of a specified minimum amount of common stock in such offering.
- The subordinated convertible debt automatically converted into Egalet Corporation common stock immediately prior to the consummation of Egalet Corporation's initial public offering, based on a conversion price equal to 50% of the per share price in such offering, which was $12 per share.
- The senior convertible debt automatically converted into Egalet Corporation common stock immediately prior to the consummation of Egalet Corporation's initial public offering, based on a conversion price equal to 50% of the per share price in such offering, which was $12 per share.